How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Leukomed Sorbact for preventing surgical site infection

    Closed for comments This consultation ended on at   Request commenting lead permission

    1 Recommendations

    1.1 Evidence supports the case for adopting Leukomed Sorbact for closed surgical wounds after caesarean section and vascular surgery in the NHS.

    1.2 Leukomed Sorbact should be considered as an option for people with wounds that are expected to have low to moderate exudate. It should be used as part of usual measures to help reduce the risk of surgical site infections.

    1.3 Cost modelling shows that the reduced rate of surgical site infections with Leukomed Sorbact compared with standard surgical dressings leads to savings of:

    • £107.43 per person after caesarean section

    • £17.82 per person after vascular surgery.

    By adopting this technology, the NHS may save up to £860,000 per year for caesarean section and up to £14,000 per year for vascular surgery. For more details, see the NICE resource impact report.

    Why the committee made these recommendations

    Leukomed Sorbact is an interactive dressing that binds to the microbes that cause surgical site infections so they are removed when the dressing is changed.

    Evidence suggests that using Leukomed Sorbact instead of standard dressings after caesarean section and vascular surgery reduces the rate of surgical site infections and leads to cost savings. So Leukomed Sorbact is recommended for wounds expected to have low to moderate exudate.